Reactivation of Herpesvirus in Patients With Hepatitis C Treated With Direct-Acting Antiviral Agents

Clinical Gastroenterology and Hepatology

Volumn 14, Issue 11, 2016, Pages 1662-1666.e1

  Perelló M , Christie ^a   Fernández Carrillo, Carlos ^a   Londoño, María Carlota ^b   Arias Loste, Teresa ^c   Hernández Conde, Marta ^a   Llerena, Susana ^c   Crespo, Javier ^c   Forns, Xavier ^b   Calleja, José Luis ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Antiviral Immune Response; Hepatitis C Virus; Varicella Zoster Virus; Viral Reactivation

Indexed keywords

ANTIVIRUS AGENT; DASABUVIR; FAMCICLOVIR; LEDIPASVIR; OMBITASVIR; PARITAPREVIR; RIBAVIRIN; RITONAVIR; SIMEPREVIR; SOFOSBUVIR; VALACICLOVIR;

ADULT; AGED; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; HEPATITIS C; HERPES SIMPLEX; HERPESVIRIDAE; HUMAN; KERATO UVEITIS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; POSTHERPETIC NEURALGIA; SPAIN; TREATMENT RESPONSE; UVEITIS; VIRAL CLEARANCE; VIRUS REACTIVATION; CASE REPORT; CHEMICALLY INDUCED; COHORT ANALYSIS; COMPLICATION; DRUG EFFECTS; HEPATITIS C, CHRONIC; HERPES SIMPLEX KERATITIS; PHYSIOLOGY; VIRUS ACTIVATION;

AGED; ANTIVIRAL AGENTS; COHORT STUDIES; HEPATITIS C, CHRONIC; HERPESVIRIDAE; HUMANS; KERATITIS, HERPETIC; MIDDLE AGED; NEURALGIA, POSTHERPETIC; SPAIN; VIRUS ACTIVATION;

EID: 84995476672     PISSN: 15423565     EISSN: 15427714     Source Type: Journal    
DOI: 10.1016/j.cgh.2016.05.016     Document Type: Article

References (18)

1. 1 Londono, M.C., Perello, C., Cabezas, J., et al. The addition of a protease inhibitor increases the risk of infections in patients with hepatitis C-related cirrhosis. J Hepatol 62 (2015), 311–316.
2. 2 Carrion, J.A., Martinez-Bauer, E., Crespo, G., et al. Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: a retrospective study. J Hepatol 50 (2009), 719–728.
3. 3 Grinde, B., Herpesviruses: latency and reactivation–viral strategies and host response. J Oral Microbiol, 5, 2013, 22766.
4. 4 Roizman, B., Carmichael, L.E., Deinhardt, F., et al. Herpesviridae. Definition, provisional nomenclature, and taxonomy. The Herpesvirus Study Group, the International Committee on Taxonomy of Viruses. Intervirology 16 (1981), 201–217.
5. 5 Humar, A., Washburn, K., Freeman, R., et al. An assessment of interactions between hepatitis C virus and herpesvirus reactivation in liver transplant recipients using molecular surveillance. Liver Transpl 13 (2007), 1422–1427.
6. 6 Pavlopoulou, I.D., Poulopoulou, S., Melexopoulou, C., et al. Incidence and risk factors of herpes zoster among adult renal transplant recipients receiving universal antiviral prophylaxis. BMC Infect Dis, 15, 2015, 285.
7. 7 Kimball, P., Verbeke, S., Shiffman, M., HCV core protein augments cyclosporine immunosuppression. Transplant Proc 37 (2005), 652–653.
8. 8 Martin, B., Hennecke, N., Lohmann, V., et al. Restoration of HCV-specific CD8+ T cell function by interferon-free therapy. J Hepatol 61 (2014), 538–543.
9. 9 Hartling, H.J., Gaardbo, J.C., Ronit, A., et al. Impaired thymic output in patients with chronic hepatitis C virus infection. Scand J Immunol 78 (2013), 378–386.
10. 10 Serti, E., Chepa-Lotrea, X., Kim, Y.J., et al. Successful interferon-free therapy of chronic hepatitis C virus infection normalizes natural killer cell function. Gastroenterology 149 (2015), 190–200 e192.
11. 11 Ende, A.R., Kim, N.H., Yeh, M.M., et al. Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report. J Med Case Rep, 9, 2015, 164.
12. 12 Collins, J.M., Raphael, K.L., Terry, C., et al. Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir. Clin Infect Dis 61 (2015), 1304–1306.
13. 13 European Medicines Agency (EMA). EMA reviews direct-acting antivirals for hepatitis C review to investigate possible hepatitis B re-activation. London: European Medicines Agency (EMA), 2016;EMA/199242/2016.
14. 14 Tsang, C.S., Samaranayake, L.P., Immune reconstitution inflammatory syndrome after highly active antiretroviral therapy: a review. Oral Dis 16 (2010), 248–256.
15. 15 Daar, E.S., Potent antiretroviral therapy does more than just decrease viral load. Clin Infect Dis 27 (1998), 1514–1516.
16. 16 Meissner, E.G., Wu, D., Osinusi, A., et al. Endogenous intrahepatic IFNs and association with IFN-free HCV treatment outcome. J Clin Invest 124 (2014), 3352–3363.
17. 17 Reig, M., Marino, Z., Perello, C., et al. Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution. J Hepatol, 2016 Epub ahead of print.
18. 18 Hales, C.M., Harpaz, R., Ortega-Sanchez, I., et al. Update on recommendations for use of herpes zoster vaccine. MMWR Morb Mortal Wkly Rep 63 (2014), 729–731.